Tag Archives: gets

BMS deal quest gets a boost as Celgene swats aside another Revlimid patent challenge

Much of the investor doubt surrounding Bristol-Myers Squibb’s $ 74 billion Celgene buyout centers on the multiple myeloma blockbuster Revlimid—namely, whether its remaining patents can stand up to legal challenges. But the companies just scored a win in that department. Thursday, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) decided not… Read More »

Who gets to decide when a 14-year-old wants to change gender? The child, the hospital, the battling parents?

In many ways, Max is a typical 14-year-old. He eschews soft music in favour of rock and heavy metal, likes to wear hoodies, giggles when he’s nervous and has a flair for drawing animals. He can be opinionated and sarcastic one moment, shy and withdrawn the next. His insecurities, however, run deeper than run-of-the-mill teenaged… Read More »